CBD Life Sciences Inc. (CBDL) Announces Groundbreaking 100MG Full Spectrum CBD Gummy Geared Toward Mental Health & Focus
SCOTTSDALE, AZ / ACCESS Newswire / April 22, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL) a leader in cannabinoid-driven health innovation - proudly announces the launch of its most anticipated product to date: a high-dosage 100MG Full Spectrum CBD Gummy, meticulously formulated to support mental health, daily focus, and emotional well-being.
Available in mouth-watering Crisp Green Apple and Wild Blueberry flavors, this isn't your average CBD gummy. It's a next-generation wellness tool - designed not only to relax the body but to sharpen the mind. Crafted with full-spectrum cannabinoids, these gummies are being positioned as a natural ally in the pursuit of mental clarity, balance, and daily productivity.
'Mental health isn't a trend - it's a global crisis. And people are tired of band-aid solutions,' said Lisa Nelson, President & CEO of CBD Life Sciences Inc. 'This product was built to empower people who want to feel better and function better - without the side effects of traditional pharmaceuticals. It's a powerful, natural alternative that speaks directly to the stress, anxiety, and attention struggles millions face every day.'
Lab tested and verified with Certificates of Analysis (COAs), this 100MG gummy represents the company's deepest push yet into the lucrative mental wellness category. Unlike many low-dose competitors, CBDL's bold formulation is made for people who need real results - entrepreneurs, creatives, students, parents, and professionals looking to stay in control of their mood and mindset.
Early conversations with several wellness clinics and mental health centers are already in progress, exploring how this high-potency gummy could be integrated into patient routines. While no formal agreements have been made, the demand is clear: health professionals are actively seeking natural, high-quality, lab-verified CBD options to complement modern mental wellness protocols.
CBDL is rapidly building a portfolio that taps into high-value niches: from pain relief and nano-enhanced beverages to functional CBD coffee creamers and now, this cutting-edge product for mental clarity. The company's ability to stay ahead of trends and deliver results has attracted attention from both investors and the wellness industry.
'We're not trying to follow the market - we're reshaping it,' Nelson added. 'With this launch, we're doubling down on our belief that the future of wellness lies in functional, focused, and effective cannabinoid products.'
This release is a bold statement to shareholders and the industry: CBD Life Sciences Inc. is serious about mental health. The company's momentum continues to build, and with this new launch, they're inviting wellness professionals, retail buyers, and everyday users to experience the next level of what CBD can offer.
The 100MG Mental Health Gummies are available now, with full lab reports and wholesale interest forms available on the company's website.
For product information, COAs, or wholesale inquiries, please visit www.thecbdvault.com.
About CBD Life Sciences Inc.
CBD Life Sciences Inc. (CBDL) is a leading innovator in the wellness and alternative health sector, specializing in high-quality CBD and functional mushroom products designed to enhance well-being. With a commitment to scientific research and consumer safety, CBDL continues to push the boundaries of holistic health solutions, creating opportunities for exponential growth in a rapidly evolving market.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: [email protected]
Stay Connected & Be the First to Try Our New Functional Mushroom Products!
Mushroom Madness Instagram: https://www.instagram.com/mushroom.madnessaz
Mushroom Madness Website: https://www.mushroommadness.shop
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
[email protected]
4802091720
SOURCE: CBD Life Sciences, Inc.
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
2 hours ago
- Associated Press
CDx Diagnostics Receives FDA Breakthrough Device Designation for Its WATS3D Test System for Esophageal Cancer
Novel AI-powered laboratory test for diagnosis of Barrett's esophagus, with or without dysplasia SUFFERN, NEW YORK / ACCESS Newswire / July 24, 2025 / CDx Diagnostics announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for its proprietary WATS3D diagnostic system, a 'first-of-a-kind' AI-powered digital pathology system using wide area transepithelial sampling for the diagnosis of Barrett's esophagus and early neoplastic alterations in patients at risk for disease progression. 'The Breakthrough Device Designation recognizes what the volume of clinical data has shown: the WATS3D Test improves the ability to detect dysplasia in Barrett's esophagus, offering patients and physicians an improved method of detection of patients at risk of development of esophageal cancer,' said Robert Odze, MD, a leading gastrointestinal pathologist. To meet the requirements for FDA Breakthrough Device Designation, CDx Diagnostics submitted technical and clinical evidence from large multi-center studies showing that the WATS3D Test is 'more effective' than the Seattle biopsy protocol for the diagnosis of Barrett's esophagus, dysplasia and esophageal cancer. 'With data from greater than 23,000 patients, the WATS3D Test continues to demonstrate its potential to detect early-stage neoplastic disease that might be missed with conventional biopsies,' said Karen Hoffman, MD, Director of R&D at CDx Diagnostics. 'This designation recognizes the science behind our platform and supports our ongoing efforts to improve early detection of patients at risk.' The WATS3D Test System leverages proprietary artificial intelligence (AI) enabled algorithm for analysis of high-resolution digital pathology using novel 3-dimensional images from specimens collected using the WATS3D brush to identify precancerous and cancerous cells and assess the risk of progression to cancer. The WATS3D System was developed by CDx Diagnostics and is performed in the company's CLIA-certified, CAP accredited, New York state licensed clinical laboratory in Suffern, NY. For more information, visit or contact us at [email protected]. About CDx Diagnostics CDx Diagnostics' mission is to Empower Physicians with Innovative Technology to Prevent Esophageal Cancer, One Patient at a Time. CDx Diagnostics is changing the landscape of cancer prevention and diagnosis through innovative AI-driven digital pathology solutions developed and performed in the company's CLIA-certified, CAP accredited clinical laboratory in Suffern, New York. The company's first advanced diagnostic test- the WATS3D Test system powered by the WATS3D Esophageal AI Algorithm - has FDA Breakthrough Device Designation for the diagnosis of Barrett's esophagus (BE), with and without dysplasia. About the WATS3D Test System The WATS3D Test system is an AI-powered digital pathology test system that helps prevent the progression of neoplasia via more effective identification of Barrett's esophagus (BE), low-grade dysplasia (LGD), high-grade dysplasia (HGD), and esophageal adenocarcinoma (EAC). Developed and performed by CDx Diagnostics, the WATS3D Test leverages artificial intelligence (AI) enabled analysis using the WATS3D Esophageal AI Algorithm and 3D digital imaging of samples collected using a WATS3D brush to identify precancerous and cancerous cells and evaluate the risk of progression to cancer. The WATS3D Test has been used to analyze over 400,000 patient samples to identify those requiring earlier intervention, reduce time to treatment, and improve patient outcomes. Contact Information William Standwill Marketing [email protected] 845-777-7000 SOURCE: CDx Diagnostics press release
Miami Herald
2 days ago
- Miami Herald
Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
Sublingual nano technology delivers 50mg of caffeine rapidly to the body, bringing its unique benefits to the pre-workout market ESTERO, FL / ACCESS Newswire / July 22, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending supplement delivery technology, today announced it plans to launch its newsublingual pre-workout supplement, BUZZ BOMB™, at FitCon and FitExpo, two of the largest fitness conventions held annually in Salt Lake City, Utah (August 1-2) and Anaheim, CA, (August 2-3), respectively. Featuring 50mg of caffeine and designed to support sustained energy and mental focus, BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout market to help athletes and fitness enthusiasts maximize their performance potential. Buzz BOMB™, offered in four flavors, provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed. Unlike pre-workout products that are mixed with water and taken well before a workout, BUZZ BOMB™ is sprinkled under the tongue for immediate effect. FitCon: Mountain America ExpoCenter, Salt Lake City, UT on August 1-2, 2025, Located in Sponsor Alley FitCon is an event that brings together fitness enthusiasts, professionals, brands, and influencers in the health and wellness industry with approximately 20,000 attendees and hundreds of exhibitors. BUZZ BOMB™ is one of seven "Gold Sponsors" at FitCon, which provides benefits including samples provided to every attendee, a large booth located along "Sponsor Alley" where all attendees pass through, as well as FitCon website marketing, advertising and communications to attendees, and a liberal exhibiting of Buzz Bomb's distinctive trademark throughout the exhibition. To learn more about FitCon, please visit The FitExpo: Anaheim Convention Center, Anaheim, CA, August 2-3, 2025, Booth #401 FitExpo brings together a diverse range of fitness brands, competitions, and demonstrations to inspire and guide individuals on their fitness journey and is one of the largest fitness conventions in the world with over 33,000 people expected to attend. As a convention sponsor, BUZZ BOMB™ will be provided numerous benefits and support, including: Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Aspire Biopharma Holdings, Inc. Contact PCG AdvisoryKevin McGrath+1-646-418-7002kevin@ SOURCE: Aspire Biopharma Holdings, Inc.
Miami Herald
2 days ago
- Miami Herald
Viemed Healthcare Announces Second Quarter 2025 Earnings Conference Call Details
LAFAYETTE, LA / ACCESS Newswire / July 22, 2025 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, today announced that it will host its Second Quarter 2025 Earnings Conference Call on Thursday, August 7, 2025, at 11:00 a.m. EDT. Interested parties may participate in the call by dialing: (877) 407-6176 (US Toll-Free) +1 (201) 689-8451 (International) Live Audio Webcast: Following the live call, a replay will be available in the Investor Relations section of the Company's website at ABOUT VIEMED HEALTHCARE, INC. Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at For further information, please contact: Investor Relationsir@ Tripp SullivanSCR Partners, LLC615-942-7077 Trae FitzgeraldChief Financial OfficerViemed Healthcare, Inc.337-504-3802 SOURCE: Viemed Healthcare, Inc.
